Industry News Abeona Therapeutics / Ellodi Pharmaceuticals BioPharma Dive

Abeona buys Phase 3-ready EoE drug from Ellodi for stock and milestones

  • Abeona acquired APT-1011, now ABO-801, an oral fluticasone treatment for eosinophilic esophagitis, from Ellodi Pharmaceuticals, a startup formed by TPG Capital.
  • Consideration is $20 million in Abeona shares plus up to $60 million in milestones tied to FDA approval and sales; Abeona also raised $30 million in a private share sale.
  • Abeona says a new Phase 3 would start in mid-2027.
Points Based on public reports

Abeona is a gene-therapy skin company, and buying a cheap, back-loaded asset in a different disease is a diversification play funded largely with paper. The risk is the Phase 3 itself: a steroid in EoE competes with approved Dupixent and budesonide products, so the new trial design has to show a clear symptom edge, and the dilution from stock plus the placement is the price shareholders pay for that option.